Publication | Open Access

Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma

UrologyGenitourinary CancerMedicineCell Death 1Kinase InhibitorsCancer TreatmentOncologyRadiation OncologyClinical Activity